Metabolic and endocrinological effects of weekly growth hormone replacement therapy with somapacitan in patients with adult growth hormone deficiency after switching from daily growth hormone replacement therapy: A real-world exploratory cohort study.

Abe I, Kubo K, Fujita Y, Ochi K, Wada T, Mitsuoka R, Takeshita K, Higashi A, Kato T, Kudo T, Shimada H, Imakyure O, Abe M, Mukoubara S, Kobayashi K

Drug discoveries & therapeutics13 Jun 2026

PMID42289325DOI10.5582/ddt.2026.01003PepBankPUB-42289325

Publisher page PubMedAsk about this study

Jump to 14 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study14

14 results from studies that gave the peptide. 14 results from people.

01HumanObservational studyEfficacy outcome
In adults with GH deficiency, BMI improved at 1 year after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, BMI improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedBMI at 1 year
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The results showed that the body mass index (BMI), fasting plasma glucose (FPG), aspartate transaminase (AST), and triglyceride (TG) levels at 1 year after switching significantly improved compared with those at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932501
02HumanObservational studyEfficacy outcome
In adults with GH deficiency, fasting plasma glucose improved at 1 year after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, fasting glucose improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedFasting plasma glucose at 1 year
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The results showed that the body mass index (BMI), fasting plasma glucose (FPG), aspartate transaminase (AST), and triglyceride (TG) levels at 1 year after switching significantly improved compared with those at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932502
03HumanObservational studyEfficacy outcome
In adults with GH deficiency, AST improved at 1 year after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, AST improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedAST at 1 year
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
The results showed that the body mass index (BMI), fasting plasma glucose (FPG), aspartate transaminase (AST), and triglyceride (TG) levels at 1 year after switching significantly improved compared with those at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932503
04HumanObservational studyEfficacy outcome
In adults with GH deficiency, triglycerides improved at 1 year after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, triglycerides improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedTriglycerides at 1 year
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
The results showed that the body mass index (BMI), fasting plasma glucose (FPG), aspartate transaminase (AST), and triglyceride (TG) levels at 1 year after switching significantly improved compared with those at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932504
05HumanObservational studyEfficacy outcome
In adults with GH deficiency, HOMA-IR improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, insulin resistance improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedHOMA-IR at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932505
06HumanObservational studyEfficacy outcome
In adults with GH deficiency, systolic blood pressure improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, systolic blood pressure improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedSystolic blood pressure at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932506
07HumanObservational studyEfficacy outcome
In adults with GH deficiency, diastolic blood pressure improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, diastolic blood pressure improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedDiastolic blood pressure at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932507
08HumanObservational studyEfficacy outcome
In adults with GH deficiency, ALT improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, ALT improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedALT at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932508
09HumanObservational studyEfficacy outcome
In adults with GH deficiency, BMI improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, BMI improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedBMI at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932509
10HumanObservational studyEfficacy outcome
In adults with GH deficiency, fasting plasma glucose improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, fasting glucose improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedFasting plasma glucose at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932510
11HumanObservational studyEfficacy outcome
In adults with GH deficiency, triglycerides improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, triglycerides improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedTriglycerides at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932511
12HumanObservational studyEfficacy outcome
In adults with GH deficiency, AST improved at 2 years after switching to somapacitan versus the switch assessment (P < 0.025).
In plain wordsIn adults with GH deficiency, AST improved after switching to somapacitan compared with the switch assessment.
Peptide
Somapacitan
Outcome
Direction not reportedAST at 2 years
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
At 2 years, the homeostasis model assessment of insulin resistance (HOMA-IR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and alanine aminotransferase (ALT), as well as BMI, FPG, TG, and AST significantly improved compared with those observed at the time of switching (each P < 0.025).
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932512
13HumanObservational studyOther
In adults switched to somapacitan, HOMA-IR improvement at 2 years was significantly associated with AST improvement.
In plain wordsIn adults switched to somapacitan, improvement in insulin resistance was linked to improvement in AST.
Peptide
Somapacitan
Outcome
Not applicableHOMA-IR and AST improvement association
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
In addition, improvement in HOMA-IR at 2 years after switching was significantly associated with improvement in AST.
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932513
14HumanObservational studyEfficacy outcome
In adults with GH deficiency, switching to somapacitan did not affect endocrinological parameters.
In plain wordsIn adults with GH deficiency, endocrinological measures did not change after switching to somapacitan.
Peptide
Somapacitan
Outcome
No significant changeEndocrinological parameters
Study
n: not reported in source
Comparator
At the time of switching from daily GH
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Switching to GH replacement therapy did not affect endocrinological parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
The metabolic and endocrinological effects in patients with adult growth hormone deficiency (AGHD) who switched from daily growth hormone (GH) replacement therapy to weekly GH replacement therapy with somapacitan were evaluated and observed over a long follow-up period. Patients were included only i…
Summary · context
Metabolic and endocrinological parameters were assessed at the time of switching, and at 1- and 2-year follow-up after switching from daily GH replacement therapy to weekly GH replacement therapy with somapacitan.
Report a problemFND-4228932514

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.